Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema

To assess long-term efficacy and safety of intravitreal inserts releasing 0.2 μg/d (low dose) or 0.5 μg/d (high dose) fluocinolone acetonide (FAc) in patients with diabetic macular edema (DME). Two randomized, sham injection-controlled, double-masked, multicenter clinical trials. Subjects with persi...

Full description

Saved in:

Bibliographic Details
Published in:	Ophthalmology (Rochester, Minn.) Vol. 119; no. 10; p. 2125
Main Authors:	Campochiaro, Peter A, Brown, David M, Pearson, Andrew, Chen, Sanford, Boyer, David, Ruiz-Moreno, Jose, Garretson, Bruce, Gupta, Amod, Hariprasad, Seenu M, Bailey, Clare, Reichel, Elias, Soubrane, Gisele, Kapik, Barry, Billman, Kathleen, Kane, Frances E, Green, Kenneth
Format:	Journal Article
Language:	English
Published:	United States 01.10.2012
Subjects:	Antihypertensive Agents - therapeutic use Cataract - etiology Cataract - therapy Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Double-Blind Method Drug Implants Fluocinolone Acetonide - administration & dosage Fluocinolone Acetonide - adverse effects Fluorescein Angiography Follow-Up Studies Glaucoma - etiology Glaucoma - surgery Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Humans Macular Edema - diagnosis Macular Edema - drug therapy Phacoemulsification Tomography, Optical Coherence Trabeculectomy Treatment Outcome Visual Acuity - physiology Vitreous Body
ISSN:	1549-4713, 1549-4713
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!